Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.54 |
| ▸ | BCR | P11274 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 12/20 | 0.53 |
| ▸ | BRAF | P15056 | 12/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967530 | 1.00 | ABL1 (0.54) | ABL1BCREGFRBRAFKIT | |
| SCHEMBL27081498 | 0.92 | ABL1 (0.58) | ABL1BCREGFRBRAFKIT | |
| SCHEMBL29967913 | 0.92 | ABL1 (0.58) | ABL1BCREGFRBRAFKIT | |
| SCHEMBL27081777 | 0.89 | FGFR1 (0.53) | ABL1BCREGFRBRAFKIT | |
| SCHEMBL29968011 | 0.88 | ABL1 (0.53) | ABL1BCREGFRBRAFKIT | |
| SCHEMBL27081727 | 0.88 | ABL1 (0.53) | ABL1BCREGFRBRAFKIT | |
| SCHEMBL27083097 | 0.87 | EGFR (0.68) | ABL1BCREGFRBRAFFGFR1 | |
| SCHEMBL27083161 | 0.86 | BRAF (0.68) | ABL1BCREGFRBRAFKIT | |
| SCHEMBL27082256 | 0.85 | BRAF (0.58) | ABL1BCREGFRBRAFKIT | |
| SCHEMBL27083160 | 0.85 | BRAF (0.68) | ABL1BCREGFRBRAFKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313972-B1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-01-29 | — | — | EP | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| EP-4313972-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | ABL1 284/4885BCR 1069/4885EGFR 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.